Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and Caucasians.
Asian Pacific journal of allergy and immunology(2022)
摘要
The clinical efficacy and safety of omalizumab was comparable among Chinese and Caucasian patients with moderate-to-severe asthma supporting therapeutic effectiveness, irrespective of race, ethnicity and geographical factors.
更多查看译文
关键词
Asthma,omalizumab,Caucasian,Chinese,comparative analysis
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络